Share-based Payment Arrangement, Expense of CAPRICOR THERAPEUTICS, INC. from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CAPRICOR THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • CAPRICOR THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,997,348, a 95% increase year-over-year.
  • CAPRICOR THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $15,679,576, a 68% increase year-over-year.
  • CAPRICOR THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $9,765,164, a 32% increase from 2023.
  • CAPRICOR THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $7,392,396, a 66% increase from 2022.
  • CAPRICOR THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $4,458,578, a 50% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

CAPRICOR THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $15,679,576 $3,997,348 +$1,946,065 +95% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $13,733,511 $3,647,153 +$1,494,360 +69% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $12,239,151 $5,739,399 +$2,473,987 +76% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $9,765,164 $2,295,676 +$433,969 +23% 01 Oct 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
Q3 2024 $9,331,195 $2,051,283 +$334,090 +19% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $8,997,105 $2,152,793 +$534,081 +33% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $8,463,024 $3,265,412 +$1,070,628 +49% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $7,392,396 $1,861,707 +$713,495 +62% 01 Oct 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
Q3 2023 $6,678,901 $1,717,193 +$630,060 +58% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $6,048,841 $1,618,712 +$460,808 +40% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $5,588,033 $2,194,784 +$1,129,455 +106% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $4,458,578 $1,148,212 +$368,062 +47% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q3 2022 $4,090,516 $1,087,133 +$366,852 +51% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $3,723,664 $1,157,904 +$445,605 +63% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $3,278,059 $1,065,329 +$312,367 +41% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $2,965,692 $780,150 +$306,405 +65% 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
Q3 2021 $2,659,287 $720,281 +$233,504 +48% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $2,425,783 $712,299 +$7,949 +1.1% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $2,417,834 $752,962 +$465,155 +162% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $1,952,679 $473,745 +$345,412 +269% 01 Oct 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $1,607,267 $486,777 +$261,509 +116% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,345,758 $704,350 +$580,133 +467% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $765,625 $287,807 +$64,641 +29% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q4 2019 $700,984 $128,333 -$252,230 -66% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
Q3 2019 $953,214 $225,268 -$205,165 -48% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $1,158,379 $124,217 -$299,017 -71% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $1,457,396 $223,166 -$211,697 -49% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 $1,669,093 $380,563 -$32,774 -7.9% 01 Oct 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q3 2018 $1,701,867 $430,433 +$2,951 +0.69% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $1,698,916 $423,234 +$25,145 +6.3% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $1,673,771 $434,863 -$36,927 -7.8% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $1,710,698 $413,337 01 Oct 2017 31 Dec 2017 10-K 29 Mar 2019 2018 FY
Q3 2017 $427,482 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $398,089 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018 2018 Q2
Q1 2017 $471,790 +$181,204 +62% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1
Q1 2016 $1,283,100 $290,586 -$281,535 -49% 01 Jan 2016 31 Mar 2016 10-Q 13 May 2016 2016 Q1
Q4 2015 $1,564,635 $382,657 +$243,113 +174% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2016 2015 FY
Q3 2015 $1,321,522 $266,927 +$118,440 +80% 30 Jun 2015 30 Sep 2015 10-Q 13 Nov 2015 2015 Q3
Q2 2015 $1,203,082 $342,930 +$235,268 +219% 01 Apr 2015 30 Jun 2015 10-Q 14 Aug 2015 2015 Q2
Q1 2015 $967,814 $572,121 +$487,577 +577% 01 Jan 2015 31 Mar 2015 10-Q 13 May 2016 2016 Q1
Q4 2014 $480,237 $139,544 +$53,744 +63% 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q3 2014 $426,493 $148,487 +$76,846 +107% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015 2015 Q3
Q2 2014 $349,647 $107,662 +$42,883 +66% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q2
Q1 2014 $306,764 $84,544 +$43,171 +104% 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015 2015 Q1
Q4 2013 $263,593 $85,800 +$78,353 +1052% 01 Oct 2013 31 Dec 2013 10-K 16 Mar 2015 2014 FY
Q3 2013 $185,240 $71,641 +$20,431 +40% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2014 2014 Q3
Q2 2013 $164,809 $64,779 -$17,439 -21% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014 2014 Q2
Q1 2013 $182,248 $41,373 -$130,442 -76% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014 2014 Q1
Q4 2012 $312,690 $7,447 01 Oct 2012 31 Dec 2012 10-K 21 Jun 2013 2012 FY
Q3 2012 $51,210 -$197,786 -79% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3
Q2 2012 $82,218 -$88,323 -52% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q2
Q1 2012 $171,815 01 Jan 2012 31 Mar 2012 10-Q 21 Jun 2013 2013 Q1
Q3 2011 $248,996 01 Jul 2011 30 Sep 2011 10-Q 21 Jun 2013 2012 Q3
Q2 2011 $170,541 01 Apr 2011 30 Jun 2011 10-Q/A 10 Sep 2012 2012 Q2

CAPRICOR THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,765,164 +$2,372,768 +32% 01 Jan 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
2023 $7,392,396 +$2,933,818 +66% 01 Jan 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
2022 $4,458,578 +$1,492,886 +50% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
2021 $2,965,692 +$1,013,013 +52% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
2020 $1,952,679 +$1,251,695 +179% 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
2019 $700,984 -$968,109 -58% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
2018 $1,669,093 -$41,605 -2.4% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
2017 $1,710,698 01 Jan 2017 31 Dec 2017 10-K 29 Mar 2019 2018 FY
2015 $1,564,635 +$1,084,398 +226% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2016 2015 FY
2014 $480,237 +$216,644 +82% 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
2013 $263,593 -$49,097 -16% 01 Jan 2013 31 Dec 2013 10-K 16 Mar 2015 2014 FY
2012 $312,690 -$472,898 -60% 01 Jan 2012 31 Dec 2012 10-K 21 Jun 2013 2012 FY
2011 $785,588 01 Jan 2011 31 Dec 2011 10-K 21 Jun 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.